| Code | CSB-RA011664MB2HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is developed as a research-grade biosimilar to sirukumab, targeting interleukin-6 (IL-6), a pleiotropic pro-inflammatory cytokine that plays a central role in immune regulation and inflammatory responses. IL-6 mediates its effects through both classical and trans-signaling pathways, influencing acute phase responses, B-cell differentiation, T-cell activation, and hematopoiesis. Dysregulated IL-6 production is implicated in numerous pathological conditions, including rheumatoid arthritis, systemic lupus erythematosus, inflammatory bowel disease, cytokine release syndrome, and various malignancies where it promotes tumor progression and resistance to therapy.
Sirukumab is a human IgG1κ monoclonal antibody that binds IL-6 with high affinity, neutralizing its biological activity by preventing interaction with both membrane-bound and soluble IL-6 receptors. This biosimilar provides researchers with a valuable tool for investigating IL-6-mediated signaling pathways, exploring inflammatory disease mechanisms, evaluating therapeutic intervention strategies, and studying cytokine networks in immunological research and oncology models.
There are currently no reviews for this product.